Bioretec Ltd.
0.02
EUR
0.00
(0.00%)
ISIN
FI4000480454
Return %
Stock
S&P 500
1Y
-83.29
14.20
3Y
-89.97
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Sarah Frances van Hellenberg Hubar-Fisher
- Full Time Employees
- 60
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Tampere Finland
- IPO Date
- Sep 28, 2021
- Website
- bioretec.com
- Similar Companies
- Business
- Bioretec Ltd. is a Finland-based medical device company that develops, manufactures, and commercializes bioresorbable orthopedic implants and biomaterials for pediatric and adult trauma and orthopedic surgery. Founded in 2003 and headquartered in Tampere, Finland, the company specializes in bioabsorbable surgical technologies designed to promote bone healing and naturally degrade within the human body, thereby eliminating the need for secondary implant removal surgeries. Bioretec categorizes its core commercial offerings into two primary material platforms: the Activa polymer-based product family, which utilizes proprietary self-reinforcing technology and includes ActivaScrew and ActivaScrew Cannulated for fracture fixation, arthrodeses, and osteotomies; ActivaScrew Interference for cruciate ligament reconstructions in sports medicine; ActivaPin and ActivaNail for small bone and pediatric fracture fixation; and ActivaIM-Nail for pediatric long-bone fracture stabilization; and the RemeOs bioresorbable metal product family, which incorporates a proprietary magnesium alloy that combines high mechanical load-bearing strength with natural bioresorbability and osteopromotive characteristics, including RemeOs compression screws and trauma screws for fracture repair and deformity correction. The company distributes its medical devices globally across North America, Europe, the Middle East, Latin America, and the Asia-Pacific region, serving hospitals, outpatient surgical centers, and trauma clinics through a network of independent distributors and specialized sales partners. In recent developments, Bioretec secured U.S. Food and Drug Administration (FDA) market clearance for its RemeOs bioresorbable magnesium screw, representing the first bioresorbable metallic implant cleared for orthopedic trauma indications in the United States, and commenced its phased commercial launch across selected U.S. hospital systems. To support commercial scaling and the clinical pipeline, the company completed multiple strategic financing rounds, expanded international distribution agreements, invested in scaling manufacturing capabilities at its Tampere cleanroom facilities, and advanced regulatory submission processes under the European Union Medical Device Regulation (EU MDR) for the RemeOs product portfolio.